<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Neuroscience Physiology and Pharmacology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/27FEBC0F-8A74-49A7-A64F-AF63BEBA765A"><gtr:id>27FEBC0F-8A74-49A7-A64F-AF63BEBA765A</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:otherNames>Philip</gtr:otherNames><gtr:surname>Hunt</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F0D18E15-0CC6-43BA-8E83-75501539A486"><gtr:id>F0D18E15-0CC6-43BA-8E83-75501539A486</gtr:id><gtr:firstName>Susan</gtr:firstName><gtr:otherNames>Clare</gtr:otherNames><gtr:surname>Stanford</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/28D1D01E-DF6A-4AAE-9BDF-0E1013164105"><gtr:id>28D1D01E-DF6A-4AAE-9BDF-0E1013164105</gtr:id><gtr:firstName>Hugh Malcolm</gtr:firstName><gtr:surname>Gurling</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0801038"><gtr:id>2A00138D-E6C5-47B8-8555-C34313F08227</gtr:id><gtr:title>NK1R knockout mouse model and human genetics of Attention Deficit Hyperactivity Disorder</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801038</gtr:grantReference><gtr:abstractText>Attention Deficit Hyperactivity Disorder (ADHD) affects about 2-5% of children and adults in the UK. Its main features are hyperactivity, impulsivity and inattentiveness. ADHD is heritable and often co-exists with other psychiatric problems, especially alcoholism and bipolar disorder (manic depression). Front-line medication includes drugs that are described as ?psychostimulants? (e.g amphetamine). However, little is known about their long-term effects, especially in children, and there is a pressing need for alternative drug treatments. Recently, we discovered that a mutant mouse, which lacks so-called NK1 receptors (?NK1R knockout?), is hyperactive. Moreover, this striking behaviour is prevented by drugs used to treat humans with ADHD. Arising from these findings, we are developing the NK1R knockout mouse as an animal model of ADHD. In this project, we shall refine this model by investigating whether these mice are impulsive and/or inattentive, as well as hyperactive. We shall also test our proposal that their abnormal behaviour is explained by disrupted regulation of the neurotransmitters, dopamine and acetylcholine, in two brain regions that have been linked with ADHD. 
Prompted by these studies in mice, we have also discovered mutations (single nucleotide polymorphisms) in the human equivalent of the NK1R gene (known as TACR1) in DNA from patients with ADHD. Our evidence suggests that these polymorphisms can be used as a diagnostic marker for ADHD. It is also possible that certain mutations in the TACR1 gene increase susceptibility of ADHD patients to alcoholism and/or bipolar disorder. In this project, we shall map the TACR1 gene in DNA from ADHD patients and confirm which of the mutations we have identified are associated with ADHD and/or alcoholism or bipolar disorder. 
The combined results of these experiments will help to refine the use of both mutant (NKR1 /-) mice, as a much needed animal model of ADHD, and mutations in the TACR1 gene as a diagnostic test for ADHD. They will also cast light on the functional abnormalities in the brain arising from a deficit in NK1R/TACR1 function. All this information will inform future investigations aimed at developing novel treatment strategies (including the potential for a new class of drug treatment) for ADHD.</gtr:abstractText><gtr:technicalSummary>Mice with functional ablation of the NK1 receptor (NK1R-/-) express hyperactivity, which is prevented by psychostimulants. They also have deficits in dopaminergic transmission in the prefrontal cortex and dorsal striatum. All these abnormalities are consistent with NK1R /- mice being a model of Attention Deficit Hyperactivity Disorder (ADHD). This proposal was confirmed in studies in which we found an association between four single nucleotide polymorphisms in the TACR1 (the human NK1R) gene and a diagnosis of ADHD. We have further evidence for polymorphisms in the TACR1 gene and increased susceptibility to alcoholism and/or bipolar disorder (BPAD). One aim of this project is to refine this mouse model of ADHD. We shall use the 5-Choice Serial Reaction Time task to establish whether NK1R-/- mice express other core features of ADHD, namely, impulsivity / inattentiveness, as well as hyperactivity. We shall also use microdialysis to test our hypothesis that, as well as disruption of dopaminergic transmission in NK1R-/- mice, there is a deficit in acetylcholine release from striatal interneurones: these neurons govern striatal output and so have a key role in regulating behaviour. We shall go on to investigate whether behavioural and neurochemical abnormalities are abolished by psychostimulants, which are used to treat ADHD, and mimicked by giving an NK1R antagonist to wild type mice. All these experiments will have a multifactorial design and the mice will be assigned randomly to the different groups. In parallel studies, we shall carry out genotyping of human DNA to test whether a clinical subgroup of ADHD is strongly associated with NKR1/TACR1 polymorphisms, as our evidence suggests. This will involve association studies using DNA from patients with ADHD, BPAD, alcoholism and healthy controls. We shall look for allelic and haplotype associations and identify region(s) of NK1R/TACR1 to be screened for mutations in the exons and promoter regions of NK1R/TACR1. We shall then genotype the entire sample to assess the likely role of novel mutations in susceptibility to ADHD, BPAD and alcoholism. This work will guide bioinformatics and in vitro studies of the functional consequences of promising mutations. The combined results of this translational project will help to develop the NK1R-/- mice as a much-needed mouse model of ADHD, provide essential information on TACR1 polymorphisms as a causal factor in this disorder and its comorbidity, and could open up new avenues of research in the hunt for novel treatments.</gtr:technicalSummary><gtr:fund><gtr:end>2011-09-14</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-09-15</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>611608</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Public Understanding of Psychopharmacology</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E30745C3-25FF-4E02-91CF-08D2839E0CB4</gtr:id><gtr:impact>Too soon to measure</gtr:impact><gtr:outcomeId>Goxr8JmzBiE</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Radio 4</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4CA39695-4502-4C67-A9C2-25702DE30C24</gtr:id><gtr:impact>Interview for 'Inside Science' discussing research findings suggesting that sex of experimenter influenced rodent behaviour

Further requests for interview via UCL press office</gtr:impact><gtr:outcomeId>5450e05fb6c7d6.07558327</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Scientific advice to media</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D2189F5F-6F82-4A5E-97D4-D3456B594B40</gtr:id><gtr:impact>Responding to specific questions from the programme Producer in respect of the design, objectives and scientific validity of programme content

Unknown</gtr:impact><gtr:outcomeId>707C57809D7</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Request for comment on scientific publication</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E60C696B-1FE0-4EEA-AB0B-B821862392FB</gtr:id><gtr:impact>My comments on the publication were publsihed in The Daily telegraph, The Times, daily Mail and on many websites, internationally

Closer links with UCL Press Office</gtr:impact><gtr:outcomeId>5450e1013a6464.73668480</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Television (International)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>78DA394F-1E8C-407F-AC03-7EB246B3272B</gtr:id><gtr:impact>Lead scientific contributor to two full-length television programs, about the effects of cocaine and MPTP on the brain, to be broadcast on the Discovery channel in the autumn of 2012

Not yet broadcast</gtr:impact><gtr:outcomeId>qkyaHEKUBP7</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Publication of full article in The Times</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2AE86D2E-3E68-403D-B384-9D6C5E927509</gtr:id><gtr:impact>Much positive feedback (from laboratory animal scientists and lay public) on my comments about the merits of some scientific research

request to contribute an article on my research to the UCL BSU website</gtr:impact><gtr:outcomeId>5450e2082da1e0.03353074</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>LASA Winter meeting (Care and Welfare section)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>52BA707B-2DEB-42D4-B521-614674A620A2</gtr:id><gtr:impact>I was invited to speak about our research of the NK1R-/- mouse model of ADHD, with particular emphasis on our contribution to refinement of the behavioural phenotyping of mutant mice and evaluation of their neurochemical status. There were a few research scientists in the audience but most came from other professions concerned with animal science: e.g. animal technicians and breeders, veterinary surgeons, Home Office Inspectorate, Certificate Holders, ethicists, representatives from Animal Charities (e.g. RSPCA) and managers from the industrial sector.

Too soon to identify long-term impact.</gtr:impact><gtr:outcomeId>6CD28859FD8</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RSPCA:  Lay Members' Forum 2011</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DBCA3E08-59D8-4331-A9A6-CD542E8F2E3B</gtr:id><gtr:impact>I was invited to give a talk on the ethical / welfare aspects and validity of behavioural laboratory animal science. Approximately 100 people attended the meeting, which was was open to anyone (from the general public) with an interest in the process of ethical review of the use of animals in medical and scientific research.

Much positive feedback from delegates. Some commented that it would help their input into their role on ER panels.</gtr:impact><gtr:outcomeId>qTLbtCNaydK</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>75268</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Industrial CASE scheme</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G1001602</gtr:fundingRef><gtr:id>26B387B4-76BC-496E-B9D5-372965602750</gtr:id><gtr:outcomeId>iJ5wDTSjHLm0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>41000</gtr:amountPounds><gtr:country>Australia, Commonwealth of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Industrial</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>Neumedix Health Group</gtr:fundingOrg><gtr:fundingRef>N/A</gtr:fundingRef><gtr:id>E4DD5C99-BF42-47DE-B4E4-7430FA467F1D</gtr:id><gtr:outcomeId>H6yPdUy6k2r</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>29000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Proof of Concept</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>UCL Business</gtr:fundingOrg><gtr:fundingRef>37-005 - POC</gtr:fundingRef><gtr:id>6795179B-FC14-470B-84A6-97D021123549</gtr:id><gtr:outcomeId>q9dp2UQMeHy</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>NK1 receptor 'knockout' mouse model of Attention Deficit Hyperactivity Disorder</gtr:description><gtr:grantRef>G0801038</gtr:grantRef><gtr:id>615FF81B-4531-48E2-9C3B-7B32579EFB12</gtr:id><gtr:impact>EU Company is marketing the mouse for study of ADHD and screening of candidate novel treatments</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>fpHSFgwXvQE</gtr:outcomeId><gtr:patentId>EP2114130</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Animal model for ADHD</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Regular contributor to European Summer School in Whole Animal Pharmacology (held at University of Utrecht)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>3C533747-D553-445D-A0CB-91A69883E37C</gtr:id><gtr:impact>Course aimed at resolving the skills deficit in in vivo pharmacology research</gtr:impact><gtr:outcomeId>YxkwHvFoAe4</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>https://www.linkedin.com/pulse/esswap-behavioural-pharmacology-now-on-line-joop-s-de-graaf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of NC3Rs PhD scholarship panel</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1207C34B-8789-4AB5-96A4-A1063756C452</gtr:id><gtr:impact>Better training of scientists engaged in preclinical psychopharmacology</gtr:impact><gtr:outcomeId>dX6d18e1Y9G</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Director (until 2012) of course leading to the BAP Certificate in Preclinical Psychopharmacolgy</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>2BE7EABE-B1BC-4F79-80AC-B5F71BA50D76</gtr:id><gtr:impact>Better training and appreciation of need for CPD for scientists engaged in psychopharmacolgy</gtr:impact><gtr:outcomeId>hYaoP8m7Ldo</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Responses to Home Office Consultations on implementation of EU Directive on use of animals in scientific procedures:A(SP)A</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7D63353D-0A55-40E5-B632-66BC4387D8E2</gtr:id><gtr:impact>New law in the UK now implemented</gtr:impact><gtr:outcomeId>fcE8SAN98YZ</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type><gtr:url>https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/291350/Guidance_on_the_Operation_of_ASPA.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Co-ordinated LASA's responses to (3) consultations on transposition into UK lawof EU Directive governing use of animals in scientific experiments</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0605CF9F-390A-4E5A-A966-59C37FE74CB3</gtr:id><gtr:impact>Impact cannot be measured</gtr:impact><gtr:outcomeId>e8CPa4iY7zb</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of NC3Rs working group on Experimental Design and Data Analysis.</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>D13946F1-2538-4865-B309-5A68B2A5FFBD</gtr:id><gtr:impact>The ARRIVE guidelines were developed through the discussions of this working group. They define information that must be included in manuscripts describing laboratory animal science and have been adopted by leading journals that publish work in this field.</gtr:impact><gtr:outcomeId>UUKMY3MTp2o</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Chairman: NC3Rs working group on Experimental Design and Data Analysis</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>CCC9A610-A2A1-42F3-8381-BAB0F2A9F683</gtr:id><gtr:impact>On-line EDA now launched: use being monitored but premature to comment</gtr:impact><gtr:outcomeId>ifaXWnybZde</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>https://www.nc3rs.org.uk/experimental-design-assistant-eda</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Contribution to FELASA working group on rodent identification</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>951B2FDF-F5B9-456C-92A5-2E5BB54ED6C4</gtr:id><gtr:impact>I wrote and led LASA's response to the FELASA / WG proposal that toe amputation of neonates should be the PREFERRED method for identification of laboratory rodents within the EU. We had strong welfare concerns, especially when the animals reached adulthood. This view was accepted and the EU commission decided that toe amputation, although permitted, should not be recommended as the preferred method.</gtr:impact><gtr:outcomeId>gr7w5ouhRTL</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type><gtr:url>http://www.felasa.eu/recommendations/reports/report-of-the-felasa-working-group-on-animal-identification-2013/</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>The colony of mice has been maintained by the commercial partner since 2008. However, the colony is currently being expanded to enable detailed phenotyping and distribution. The costs are being paid by the licensee under the terms agreed with UCL- Business.</gtr:description><gtr:id>3F8A640B-2F2E-46CD-A2E0-065408F9D8F9</gtr:id><gtr:impact>Growing interest in the role of NK1 receptors in ADHD. Our paper, published in PLoS ONE in May, 2011, has received 1900 'hits'.</gtr:impact><gtr:outcomeId>SGwXEv1EBQZ</gtr:outcomeId><gtr:stage>Small-scale adoption</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>NK1R-/- mouse model of ADHD</gtr:title><gtr:type>Support Tool - For Fundamental Research</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>The behavioural abnormalities expressed by the NK1R-/- ('knockout') mouse resemble those seen in humans with ADHD and include hyperactivity with deficits in cognitive performance. Neurochemical abnormalities in the brain are also consistent with our understanding of the brain mechanisms underlying this disorder and the mechanism of action of drugs used to treat ADHD.</gtr:description><gtr:id>8D0D7846-DE43-499E-803B-A377D3A042DC</gtr:id><gtr:impact>Granting of patent 17.06.2011 [EP2114130]</gtr:impact><gtr:outcomeId>KR4TUGPN85F</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>NK1R-/- mouse model of ADHD</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>FA1CADBD-98C0-444C-A2C2-BA844FEB0CA3</gtr:id><gtr:title>Psychostimulants, antidepressants and neurokinin-1 receptor antagonists ('motor disinhibitors') have overlapping, but distinct, effects on monoamine transmission: the involvement of L-type Ca2+ channels and implications for the treatment of ADHD.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b78ab2fc11237aad7706f697d269cad5"><gtr:id>b78ab2fc11237aad7706f697d269cad5</gtr:id><gtr:otherNames>Stanford SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn><gtr:outcomeId>5450ddff987034.05088746</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D8A117E-6B21-41B2-8C37-16025DB7B6BF</gtr:id><gtr:title>The NK1R-/- mouse phenotype suggests that small body size, with a sex- and diet-dependent excess in body mass and fat, are physical biomarkers for a human endophenotype with vulnerability to attention deficit hyperactivity disorder.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4aedc19a84ca453ebdc1c79b0c71323"><gtr:id>b4aedc19a84ca453ebdc1c79b0c71323</gtr:id><gtr:otherNames>Pillidge K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>58be78dc8aeb68.60956212</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>120141EA-E5CC-4278-B0FA-128F25800D8D</gtr:id><gtr:title>Atomoxetine reduces hyperactive/impulsive behaviours in neurokinin-1 receptor 'knockout' mice.</gtr:title><gtr:parentPublicationTitle>Pharmacology, biochemistry, and behavior</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4aedc19a84ca453ebdc1c79b0c71323"><gtr:id>b4aedc19a84ca453ebdc1c79b0c71323</gtr:id><gtr:otherNames>Pillidge K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0091-3057</gtr:issn><gtr:outcomeId>56b9cf3061f6f9.45539020</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4C67CC4-B8F9-496C-9985-D388BFFB4F08</gtr:id><gtr:title>Performance deficits of NK1 receptor knockout mice in the 5-choice serial reaction-time task: effects of d-amphetamine, stress and time of day.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/775c89ca0c00e5c0bd0c88cfcc94558f"><gtr:id>775c89ca0c00e5c0bd0c88cfcc94558f</gtr:id><gtr:otherNames>Yan TC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>244F859E_1244F859E_1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD531121-F2B5-4958-97FF-BD0898F47F73</gtr:id><gtr:title>Antagonism of L-type Ca(v) channels with nifedipine differentially affects performance of wildtype and NK1R-/- mice in the 5-Choice Serial Reaction-Time Task.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab13f1aa310f9f691808081d59361c3e"><gtr:id>ab13f1aa310f9f691808081d59361c3e</gtr:id><gtr:otherNames>Dudley JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn><gtr:outcomeId>pm_14184_24_22884624</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1FC477D-8F64-410F-9F6E-C598E3BF1470</gtr:id><gtr:title>The influence of test experience and NK1 receptor antagonists on the performance of NK1R-/- and wild type mice in the 5-Choice Serial Reaction-Time Task.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85f15060c9a45220985e584263201830"><gtr:id>85f15060c9a45220985e584263201830</gtr:id><gtr:otherNames>Weir RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>doi_14184_1113495722</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01D7FDB4-9A8F-4E97-8F53-AE452619CA64</gtr:id><gtr:title>Perseveration by NK1R-/- ('knockout') mice is blunted by doses of methylphenidate that affect neither other aspects of their cognitive performance nor the behaviour of wild-type mice in the 5-Choice Continuous Performance Test.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4aedc19a84ca453ebdc1c79b0c71323"><gtr:id>b4aedc19a84ca453ebdc1c79b0c71323</gtr:id><gtr:otherNames>Pillidge K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>58be789de18fa5.92608529</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A24BAFE4-2295-4459-9BC5-83BEA9A3EF21</gtr:id><gtr:title>The angiotensin converting enzyme inhibitor, captopril, prevents the hyperactivity and impulsivity of neurokinin-1 receptor gene 'knockout' mice: sex differences and implications for the treatment of attention deficit hyperactivity disorder.</gtr:title><gtr:parentPublicationTitle>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b356071a8c797e066d91a276c5975c6d"><gtr:id>b356071a8c797e066d91a276c5975c6d</gtr:id><gtr:otherNames>Porter AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0924-977X</gtr:issn><gtr:outcomeId>5675dffd24026</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DB1CAD9-37A1-4C30-B944-DBB60CACC7A6</gtr:id><gtr:title>Genetics of attention-deficit hyperactivity disorder (ADHD).</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02c18e63f80f85ded789fda5d6a3e178"><gtr:id>02c18e63f80f85ded789fda5d6a3e178</gtr:id><gtr:otherNames>Sharp SI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn><gtr:outcomeId>1BF698537BD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED760D41-3EC8-4258-87E3-2A35BA285C6C</gtr:id><gtr:title>Genetic association of the tachykinin receptor 1 TACR1 gene in bipolar disorder, attention deficit hyperactivity disorder, and the alcohol dependence syndrome.</gtr:title><gtr:parentPublicationTitle>American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02c18e63f80f85ded789fda5d6a3e178"><gtr:id>02c18e63f80f85ded789fda5d6a3e178</gtr:id><gtr:otherNames>Sharp SI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1552-4841</gtr:issn><gtr:outcomeId>pm_540e160e160a9ebad</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DEDBE186-BF00-449E-AC3C-7A64960228EF</gtr:id><gtr:title>Raised arterial blood pressure in neurokinin-1 receptor-deficient mice (NK1R(-/-) ): evidence for a neural rather than a vascular mechanism.</gtr:title><gtr:parentPublicationTitle>Experimental physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/384a71eb8a5d4e4b2d2415acf5976dfc"><gtr:id>384a71eb8a5d4e4b2d2415acf5976dfc</gtr:id><gtr:otherNames>Moyes AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0958-0670</gtr:issn><gtr:outcomeId>56c483e254d4c0.56987186</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B31E3CB4-B78C-442A-82E4-B4AF0397E91B</gtr:id><gtr:title>Differences in the performance of NK1R-/- ('knockout') and wildtype mice in the 5-Choice Continuous Performance Test.</gtr:title><gtr:parentPublicationTitle>Behavioural brain research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b356071a8c797e066d91a276c5975c6d"><gtr:id>b356071a8c797e066d91a276c5975c6d</gtr:id><gtr:otherNames>Porter AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0166-4328</gtr:issn><gtr:outcomeId>56b9ccf1a6e2d1.51746873</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6687B6AD-B1BE-4F76-A18C-08AA4528ABD6</gtr:id><gtr:title>Behavioural and neurochemical abnormalities in mice lacking functional tachykinin-1 (NK1) receptors: a model of attention deficit hyperactivity disorder.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/775c89ca0c00e5c0bd0c88cfcc94558f"><gtr:id>775c89ca0c00e5c0bd0c88cfcc94558f</gtr:id><gtr:otherNames>Yan TC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn><gtr:outcomeId>710A9DD6093</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02DC1C5F-1030-40E1-A103-33DB364F2459</gtr:id><gtr:title>A lack of functional NK1 receptors explains most, but not all, abnormal behaviours of NK1R-/- mice(1).</gtr:title><gtr:parentPublicationTitle>Genes, brain, and behavior</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b356071a8c797e066d91a276c5975c6d"><gtr:id>b356071a8c797e066d91a276c5975c6d</gtr:id><gtr:otherNames>Porter AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1601-183X</gtr:issn><gtr:outcomeId>56b9ccf17f8767.41992394</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801038</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>